Neutralizing antibody creation technologies: case of SARS-CoV-2

Author:

Baklaushev VP1ORCID,Samoilova EM1ORCID,Kuznetsova SM1,Ermolaeva EV2,Yusubalieva GM1ORCID,Kalsin VA1,Lipatova AV2,Troitsky AV1

Affiliation:

1. Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medical Biological Agency of Russia, Moscow, Russia

2. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Abstract

Monoclonal antibodies (mAbs) are the most promising and most intensively replenished type of bioactive pharmaceuticals. Currently, there are over 100 different mAbs approved by the FDA and other regulating agencies for treatment of oncological, infectious, systemic, autoimmune and other diseases. Design of antibodies neutralizing pathogens of socially significant infections, such as HIV, hepatitis viruses, SARS-CoV-2, is a separate direction. The SARS-CoV-2 pandemic has shown how urgent it is to have a technological platform enabling production of fully human antibodies. The development of recombinant DNA technology and antibody phage display enabled compilation of libraries of antigen-binding fragments and screening with target antigens. This review discusses the advantages and disadvantages of phage display, including use of single-domain antibody technology based on the heavy chain variable domain. We describe the state-of-the-art (and practical results of its application) technology enabling production of human antibodies by sorting and sequencing the genome of individual memory B cells, using monoclonal virus-neutralizing antibodies against SARS-CoV-2 as an example. The prospects of further development of the recombinant human antibody production technology are discussed; in particular, we consider creation of sequences of variable fragments of antibodies with the help of artificial intelligence.

Publisher

Federal Medical Biological Agency

Subject

Electrical and Electronic Engineering,Condensed Matter Physics,General Materials Science,Atomic and Molecular Physics, and Optics,Condensed Matter Physics,Biochemistry,General Chemistry,Atomic and Molecular Physics, and Optics,Biophysics,Literature and Literary Theory,Visual Arts and Performing Arts,History,Language and Linguistics,Industrial and Manufacturing Engineering,Computer Science Applications,Artificial Intelligence,Statistics and Probability,Control and Systems Engineering,Software,Industrial and Manufacturing Engineering,Mechanical Engineering,Safety, Risk, Reliability and Quality,Public Health, Environmental and Occupational Health,Health Policy,Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Management, Monitoring, Policy and Law,Public Administration

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3